ReviewOxford open immunology2026
Capturing the full spectrum of T cell responses with spectral flow cytometry.
Review in Oxford open immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Special Issue "Flow Cytometry: Applications and Challenges".International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over a decade has passed since the first commercial spectral flow cytometry (SFC) instrument was introduced. Unlike conventional flow cytometers, SFC utilizes an array of detectors to capture the full emission spectrum of fluorochromes, from which composite signatures are deconvoluted using an unmixing algorithm. This allows fluorochromes with overlapping peaks to be used within the same panel, enabling panels with up to 50 parameters. As its availability increases, more immunologists are looking to incorporate SFC into their experiments. One area of research benefiting from the larger SFC panels is the characterization of rare cells, including antigen-specific T cells identified directly ex vivo using either antigen stimulation or major histocompatibility complex-peptide multimers. In this brief review, we outline some practical considerations when combining ex-vivo T cell stimulation with SFC, drawing on our transition from conventional to SFC. Key aspects include designing the experiment and panel for stimulated cells, acquiring high-quality reference controls, strategies to manage autofluorescence and an overview of the data analysis, including both manual and computational approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.